The emergence of immune checkpoint inhibitors as effective cancer immunotherapy has effectively built a new “highway” connecting the promise of oncologic translational research to progress in treating advanced malignancies.
Matthew Zibelman, MD
Advertisement
Articles by Matthew Zibelman, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
2
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
3
Radiation Oncology Trials You May Have Missed at ASCO 2026
4
84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study
5